Clinical trials: Virus Diseases
Infection, Human Immunodeficiency Virus
A Study of the Relative Bioavailability of BMS-626529 Administered as BMS-663068 From 150mg Low-dose Extended-release Tablets Compared to 600mg Reference Extended-release Tablets in Healthy Subjects
An oral dose in healthy subjects to determine the relative bioavailabilty of BMS-626529 administered as BMS-663068
- Trial name
- NCT02859259
- Testing
- BMS-663068 (1 tablet at 600 mg), BMS-663068 (4 tablets at 150 mg each tablet)
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
Hepatitis B
B-Ensure: Long-term Follow-up Study to Evaluate Durability of Treatment Response in Previous Bepirovirsen Study Participants
This multi-country, longitudinal follow-up study will enrol adults with chronic hepatitis B (CHB) who previously participated in the Phase III B-Well-1 ((202009: NCT05630807) or B-Well-2 (219288: NCT05630820) studies, received 24…
- Trial name
- B-Ensure (NCT07908459)
- Testing
- Bepirovirsen
- Volunteers
- 303 people
- Sponsor
- GlaxoSmithKline
COVID-19
A Bridging Study of FB2001 in Healthy Subjects
In the first human clinical trial conducted in the United States, single and multiple dosing of FB2001 in multiple dose groups were partially completed，and FB2001 demonstrated good safety and tolerability.
- Trial name
- NCT05197179
- Testing
- FB2001
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Frontier Biotechnologies Inc.
SARS-CoV2 Infection
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)
The primary objective of this study is to provide expanded access of remdesivir (RDV) for the treatment of severe acute respiratory syndrome coronavirus (SARS-CoV2) infection.
- Trial name
- NCT04323761
- Testing
- Remdesivir
- Where
- 272 sites in United States, Australia and 25 more
- Sponsor
- Gilead Sciences
Herpes Simplex Virus Type I Stromal Keratitis
A Phase Ⅱa Study of the Safety, Tolerability and Efficacy of BD111 in Herpes Simplex Virus Type I Stromal Keratitis
This study aims to compare the clinical efficacy and safety of BD111 injection in combination with standard therapy vs. standard therapy in herpes simplex virus type I stromal keratitis (HSK), providing preliminary confirmation…
- Trial name
- NCT06474442
- Testing
- BD111 Injection (investigational new drug), Triple-drugs therapy of HSV-1 stromal keratitis
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Shanghai BDgene Co., Ltd.
Hepatitis D, Chronic
SOLSTICE: Combination Therapy for the Treatment of Chronic Hepatitis D Infection.
This is a phase 2 trial in which participants with chronic hepatitis D virus (HDV) infection will receive VIR-2218 and/or VIR-3434 and be assessed for safety, tolerability, and efficacy
- Trial name
- NCT05461170
- Testing
- VIR-2218, VIR-3434, NRTI
- Where
- 20 sites in Bulgaria, France and 7 more
- Volunteers
- 95 people
- Sponsor
- Vir Biotechnology, Inc.
X-Linked Retinitis Pigmentosa
Safety and Efficacy of rAAV2tYF-GRK1-RPGR in Subjects With X-linked Retinitis Pigmentosa Caused by RPGR Mutations
This study will evaluate the safety and efficacy of a recombinant adeno-associated virus vector (rAAV2tYF-GRK1-RPGR) in patients with X-linked retinitis pigmentosa caused by RPGR mutations.
- Trial name
- HORIZON (NCT03316560)
- Testing
- rAAV2tYF-GRK1-RPGR
- Where
- 4 sites in United States
- Volunteers
- 29 people
- Sponsor
- Beacon Therapeutics
Chronic Hepatitis C
Study of Nitazoxanide, Peginterferon Alfa-2a and Ribavirin in Treatment-Naive Hepatitis C Patients
The purpose of this study is to determine if nitazoxanide in combination with peginterferon alfa-2a and ribavirin is safe and effective in treating chronic hepatitis C in treatment-naive patients.
- Trial name
- STEALTHC-3 (NCT00637923)
- Testing
- Nitazoxanide, Peginterferon alfa-2a, Ribavirin
- Where
- 10 sites in United States
- Volunteers
- 112 people
- Sponsor
- Romark Laboratories L.C.
Anal High Grade Squamous Intraepithelial Lesion, Anal Precancerous Condition
Artesunate Suppositories for the Treatment of HIV-negative Patients With Intra-anal HSIL
This is a phase II double blind, placebo-controlled, randomized study of Artesunate suppositories for the treatment of HIV-negative men and women who have anal high grade squamous intraepithelial lesions (anal HSIL)
- Conditions
- Anal High Grade Squamous Intraepithelial Lesion, Anal Precancerous Condition, AIN 2/3, HPV Infection
- Trial name
- anal HSIL HIV- (NCT05555862)
- Testing
- Artesunate
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- Frantz Viral Therapeutics, LLC
HIV Infections
Tipranavir/Ritonavir vs. Genotypically Defined Protease Inhibitor/Ritonavir in HIV Patients (RESIST-2)
The objective of this study is to demonstrate the safety and efficacy of tipranavir/ritonavir versus an active control arm in highly treatment experienced Human immunodeficiency virus-1 infected patients.
- Trial name
- NCT00144170
- Testing
- Tipranavir (with low dose ritonavir), Comparator protease inhibitor(CPI)/low dose ritonavir(r)
- Where
- 174 sites in Argentina, Austria and 15 more
- Volunteers
- 882 people
- Sponsor
- Boehringer Ingelheim
HIV/AIDS
Safety and Pharmacokinetic Study of Oral Maraviroc and Maraviroc 1% Gel in HIV-1 Seronegative Adults
The purpose of the study is to evaluate the safety, acceptability, and PK/PD profile of maraviroc gel following rectal and vaginal administration. The study also includes oral exposure to maraviroc.
- Trial name
- NCT02346084
- Testing
- Maraviroc 300 mg tablet (PO) and Maraviroc 1% gel (PR and PV)
- Where
- United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- International Partnership for Microbicides, Inc.
Infection, Human Immunodeficiency Virus
Dose-finding Study of GSK2248761 in Antiretroviral Therapy-Naive Subjects (SIGNET)
This 96 week, Phase 2b study in 150 HIV-1 infected antiretroviral (ART) naive adult subjects consists of a dose-ranging evaluation of GSK2248761 at blinded doses of 100 mg and 200 mg once daily with a control arm of open-label…
- Trial name
- SIGNET (NCT01231555)
- Testing
- GSK2248761 100 mg once daily, GSK2248761 200 mg once daily, Efavirenz 600 mg once daily
- Where
- 12 sites in France, Germany and 1 more
- Volunteers
- 23 people
- Sponsor
- ViiV Healthcare
Viral; Infection, Coxsackie(Virus)
PROtocol for Coxsackievirus VaccinE in Healthy VoluNTteers
Phase 1, first-in-human, randomized, double-blind, placebo-controlled, multiple-dose-escalation study to evaluate the safety, tolerability and immunogenicity of PRV-101, a coxsackie virus B vaccine, in healthy volunteers.
- Trial name
- PROVENT (NCT04690426)
- Testing
- PRV-101
- Where
- Finland
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Provention Bio, Inc.
HIV-1-infection, HIV Infections
Study to Evaluate Safety, Tolerance and Efficacy of ASC22 Combined With ART in Subjects With HIV
This study is a phase II, multicenter, randomized, blind, placebo-controlled to evaluate the safety, tolerance, efficacy of ASC22 injection in combination with anti-retroviral therapy to treat subjects living with human…
- Conditions
- HIV-1-infection, HIV Infections, PD-L1 Gene Mutation
- Trial name
- NCT05330143
- Testing
- ASC22 1mg/kg, ASC22 2.5mg/kg, Antiretroviral Therapy
- Where
- China
- Volunteers
- 19 people
- Sponsor
- Ascletis Pharmaceuticals Co., Ltd.
Hepatitis E, Hepatitis B
A Phase Ⅳ Clinical Trial of the Recombinant Hepatitis E Vaccine (Escherichia Coli)(Coadministration With Recombinant Hepatitis B Vaccine)
This is a open label, randomized phase VI study, to assess the safety and immunogenicity of co-administration of Hepatitis E vaccine with Hepatitis B vaccine.
- Trial name
- NCT02584543
- Testing
- HEV vaccine, HBV vaccine
- Where
- China
- Volunteers
- 602 people, healthy volunteers welcome
- Sponsor
- Xiamen Innovax Biotech Co., Ltd
Influenza, Pandemic Influenza
Study of Swine-Origin A/H1N1 Influenza Non-Adjuvanted Vaccine in Healthy Adults in India
The purpose of this study is to assess the safety and immunogenicity of one dose of A/H1N1 non-adjuvanted pandemic vaccine to support registration of the vaccine in India.
- Conditions
- Influenza, Pandemic Influenza, Influenza A Virus, H1N1 Subtype
- Trial name
- NCT01053143
- Testing
- A/H1N1 pandemic influenza vaccine (non- adjuvanted)
- Where
- 3 sites in India
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
COVID-19
Efficacy,Immunogenicity and Safety of COVID-19 Vaccine , Inactivated Booster Dose in Adults Aged 18 Years and Above
This is a multi-center, case-driven, randomized, double-blinded, and placebo-controlled Phase Ⅲb clinical trial of COVID-19 Vaccine manufactured by Sinovac Research \& Development Co., Ltd.The purpose of this study is to evaluate…
- Trial name
- NCT05156632
- Testing
- Medium-dosage COVID-19 Vaccine,Inactivated, High-dosage COVID-19 Vaccine,Inactivated
- Volunteers
- healthy volunteers welcome
- Sponsor
- Sinovac Research and Development Co., Ltd.
HIV Infections
A Third-Party Blinded, Placebo Controlled Comparative Study of AS-101 Administered Intravenously in HIV Positive Patients With Advanced Disease
To compare the effect of AS-101 to that of placebo on clinical efficacy and immunologic function in HIV positive patients with advanced disease.
- Trial name
- NCT00002033
- Testing
- Zidovudine, AS-101
- Where
- 4 sites in Brazil
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
HIV Infection
A Long Term, Safety Study of Apricitabine in HIV-infected Subjects
The study will examine how safe and effective apricitabine is when given long term (as ongoing treatment) to HIV patients who have already completed the AVX-201 trial
- Trial name
- NCT00367952
- Testing
- apricitabine
- Where
- Australia
- Volunteers
- 42 people
- Sponsor
- Avexa
Herpes Zoster
A Study to Test GlaxoSmithKline's (GSK) Candidate Vaccine-GSK1437173A for Prevention of Shingles in Children With Kidney Transplant
The purpose of this study is to evaluate the reactogenicity, safety and immunogenicity of 2 doses of PED-HZ/su, GSK's vaccine candidate for the prevention of Herpes Zoster (HZ) in immunocompromised paediatric renal transplant…
- Trial name
- NCT04006808
- Testing
- PED-HZ/su
- Where
- 31 sites in Belgium, France and 4 more
- Volunteers
- 184 people
- Sponsor
- GlaxoSmithKline
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.